Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 4Terminated 3Completed 3Not yet recruiting 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Neoplasms 1Melanoma 1Low-grade Glioma 1Advanced Nonhematologic Malignancies 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × tovorafenib × Clear all
NCT03429803 2026-02-19

DAY101 In Gliomas and Other Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
44 enrolled
CNS

Low-grade Glioma

NCT01425008 2020-08-10

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Takeda

Phase 1 Completed
149 enrolled 43 charts
Dermatologic

Melanoma, Neoplasms

NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡